Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial

被引:0
作者
Lipton, R. [1 ]
Chalermpalanupap, N. [2 ]
Nahas-Geiger, S. [3 ]
Pozo-Rosich, P. [4 ]
McAllister, P. [5 ]
Tatsuoka, Y. [6 ]
Liu, Y. [7 ]
Dabruzzo, B. [2 ]
Smith, J. [7 ]
Bilchik, T. [8 ]
机构
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] AbbVie, Madison, NJ USA
[3] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] Tatsuoka Neurol Clin, Kyoto, Japan
[7] AbbVie, N Chicago, IL USA
[8] Yale Sch Med, New Haven, CT USA
来源
HEADACHE | 2023年 / 63卷
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P-180
引用
收藏
页码:168 / 169
页数:2
相关论文
共 50 条
[21]   Decrease in body weight with once-daily atogepant for the preventive treatment of migraine: A post hoc analysis [J].
Dodick, D. W. ;
Hay, D. L. ;
Walker, C. S. ;
Goadsby, P. J. ;
Ailani, J. ;
Severt, L. ;
Finnegan, M. ;
Ma, J. ;
Guo, H. ;
Trugman, J. M. .
HEADACHE, 2022, 62 :96-97
[22]   Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial [J].
Ailani, J. ;
Gandhi, P. ;
Dodick, D. W. ;
Reuter, U. ;
Schwedt, T. J. ;
Liu, Y. ;
Dabruzzo, B. ;
Stokes, J. ;
Lipton, R. B. .
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[23]   Patient responses to atogepant 60 mg once daily: a post hoc analysis of the ADVANCE trial [J].
Ong, J. J. Y. ;
Liu, Y. ;
Smith, J. H. ;
Carr, K. ;
Goadsby, P. J. .
JOURNAL OF HEADACHE AND PAIN, 2024, 25
[24]   Efficacy of Oral Atogepant in People With Chronic Migraine With and Without Acute Medication Overuse: Results From the PROGRESS Trial [J].
Goadsby, Peter J. ;
Friedman, Deborah I. ;
Holle-Lee, Dagny ;
Demarquay, Genevieve ;
Ashina, Sait ;
Yu, Sung Y. ;
Dabruzzo, Brett ;
Guo, Hua ;
Schwefel, Brittany ;
Trugman, Joel .
CEPHALALGIA, 2022, 42 (1_SUPPL) :34-35
[25]   Efficacy of Oral Atogepant in People With Chronic Migraine With and Without Acute Medication Overuse: Results From the PROGRESS Trial [J].
Goadsby, P. ;
Friedman, D. ;
Holle-Lee, D. ;
Demarquay, G. ;
Ashina, S. ;
Yu, S. ;
Dabruzzo, B. ;
Guo, H. ;
Schwefel, B. ;
Trugman, J. .
HEADACHE, 2023, 63 :136-136
[26]   Atogepant Provides Early Improvements in Daily Functioning and Quality of Life: Results from the PROGRESS Chronic Migraine Trial [J].
Ailani, J. ;
Dodick, D. ;
Reuter, U. ;
Schwedt, T. ;
Liu, Y. ;
Dabruzzo, B. ;
Stokes, J. ;
Gandhi, P. ;
Lipton, R. .
HEADACHE, 2023, 63 :117-118
[27]   Patient Responses to Atogepant 60 mg Once Daily: A Post hoc Analysis of the ADVANCE and PROGRESS Trials [J].
Ong, Jonathan J. Y. ;
Liu, Yingyi ;
Smith, Jonathan H. ;
Carr, Karen ;
Goadsby, Peter J. .
CEPHALALGIA, 2023, 43 (1supp)
[28]   Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis [J].
Dodick, D. ;
Lipton, R. ;
Nahas, S. ;
Pozo-Rosich, P. ;
McAllister, P. ;
Mechtler, L. ;
Ma, J. ;
Dabruzzo, B. ;
Dufek, M. ;
Severt, L. ;
Finnegan, M. ;
Trugman, J. .
JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1)
[29]   Monthly migraine days, acute medication use days, and migraine-specific quality of life in responders to atogepant: A post hoc analysis [J].
Dodick, D. W. ;
Lipton, R. B. ;
Nahas, S. J. ;
Pozo-Rosich, P. ;
McAllister, P. ;
Mechtler, L. L. ;
Ma, J. ;
Dabruzzo, B. L. ;
Dufek, M. ;
Severt, L. ;
Finnegan, M. ;
Trugman, J. M. .
HEADACHE, 2022, 62 :152-153
[30]   Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials [J].
Paul Rizzoli ;
Michael J. Marmura ;
Jennifer Robblee ;
Jennifer McVige ;
Sara Sacco ;
Stephanie J. Nahas ;
Jessica Ailani ;
Rosa De Abreu Ferreira ;
Julia Ma ;
Jonathan H. Smith ;
Brett Dabruzzo ;
Messoud Ashina .
The Journal of Headache and Pain, 25